Physician profile
Molly Recktenwald
NPI 1639834187
$4,166.51
in general payments reported to CMS, 2019-2025
26 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10.05 · 2022: $556 · 2023: $762 · 2024: $1,399 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,123.04 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $344.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $291.55 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $282.80 | 2025 | Ponvory, Hetlioz, Fanapt |
| Exact Sciences Corporation | $144.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $134.62 | 2022-2024 | Repatha, Otezla |
| Sientra, INC. | $114.09 | 2022 | |
| Dynavax Technologies Corporation | $94.41 | 2024-2025 | Heplisav-B |
| Hologic Sales and Service, LLC | $90.39 | 2022-2024 | Aptima |
| Glaxosmithkline, LLC. | $76.70 | 2023-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $65.55 | 2023-2024 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $54.19 | 2025 | Auvelity |
| Astellas Pharma US INC | $49.38 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $37.63 | 2023-2024 | Proquad, Vaxneuvance, Gardasil 9 |
| Ethicon INC. | $32.38 | 2024 | Monarch Platform |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.88 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.37 | 2024-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $27.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.39 | 2022-2023 | |
| Medtronic, INC. | $23.62 | 2025 | Symplicity G3 |
| Ardelyx, INC. | $20.69 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.36 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $16.49 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $14.54 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.22 | 2025 | Jardiance |
| Genentech USA, INC. | $10.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Recktenwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.